James Howard Tonsgard to Neurofibroma, Plexiform
This is a "connection" page, showing publications James Howard Tonsgard has written about Neurofibroma, Plexiform.
Connection Strength
0.770
-
Qualitative aspects of pain in children and adults with neurofibromatosis type 1 and plexiform neurofibromas: Causes, consequences, and communication. J Health Psychol. 2026 Mar; 31(4):1562-1574.
Score: 0.233
-
Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings. J Patient Rep Outcomes. 2025 Apr 30; 9(1):46.
Score: 0.230
-
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.
Score: 0.171
-
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr; 17(4):596-603.
Score: 0.111
-
Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod Pathol. 2013 Jul; 26(7):930-43.
Score: 0.025